Chronic Lymphocytic Leukemia


Related Videos (117)

In this presentation, hematologist­-oncologist Anthony R. Mato, MD, MSCE, offers a summary of clinical trials of new and evolving agents for the treatment of chronic lymphocytic leukemia. Among other topics, Dr. Mato reviews the BTK inhibitor ibrutinib; the P13K-­delta inhibitors idelalisib and TGR­-1202; the chimeric anti-­CD20 antibody rituximab; and the novel kinase inhibitor ublituximab.

 To see the 2016 update on CLL, click here


Penn PhysicianLink®

Penn PhysicianLink® is an exclusive program that helps all referring physicians connect with Penn Medicine. This comprehensive package of support services expedites and facilitates direct physician communication for patient consults, referrals and transfers.

Learn more about Penn PhysicianLink®